Day care and treatment

Fundació ACE achieves 78% of visits during confinement thanks to its adaptation to telemedicine

25/06/2020
Fundació ACE has successfully adapted its care model to telemedicine, in the context of the SARS-COV-2 coronavirus pandemic. Its adaptation process has been published by the Journal of Alzheimer's Disease.

New genetic study associated with Alzheimer's

24/04/2019Research
Fundació ACE participates in an international study that provides new information about a variant of the BDNF gene, called BDNFVal66Met, associated with Alzheimer's disease and cognitive decline.

Merck discontinues the Verubecestat drug study

16/04/2019Research
Merck discontinued the clinical trial of the Verubecestat drug, performed by Fundació ACE in people with Alzheimer's at a very early stage, after not obtaining the expected results.

The Foundation presents the results of AMBAR at the EADC

12/04/2019Research
Fundació ACE participated this week in the biannual meeting of the European Alzheimer's Disease Consortium (EADC) to present the results of the AMBAR study, a project opening a possible new treatment pathway for Alzheimer's.

Great public attendance at the Conference of Professor Villemagne in Fundació ACE

03/04/2019Research
Around seventy Alzheimer's and dementia professionals attended yesterday at the headquarters of Fundació ACE the conference of Professor Victor L. Villemagne on molecular neuroimaging biomarkers.

Grifols presents new data to support the effectiveness of its clinical trial to treat Alzheimer's

29/03/2019Research
Dr. Mercè Boada has participated today in the presentation of the new results of the AMBAR study. These results have been presented by Dr. Antonio Páez (GRIFOLS) at the 14th International Congress on Alzheimer's and Parkinson's (AD / PD) in Lisbon.